Drugs / KN057
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06747416 | Sep 2025 → Sep 2026 overdue | hemophilia | Suzhou Alphamab Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05421429 | Jul 2022 → Jan 2024 | hemophilia | Suzhou Alphamab Co., Ltd. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07545395 | Mar 2026 → Dec 2027 expected | hemophilia | Suzhou Alphamab Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06569108 | Apr 2024 → Oct 2026 expected | hemophilia A, hemophilia B | Suzhou Alphamab Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06312475 | Jan 2024 → Oct 2025 overdue | hemophilia A, hemophilia B | Suzhou Alphamab Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KN057 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06747416 ↗ |
| Route | Subcutaneous | “KN057 subcutaneous (SC) injection” NCT05421429 ↗ |